The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy

摘要

Glucose-lowing efficacy of therapeutic agents. The maximum value for the range in HbA1c reductions associated with each treatment is indicated by each bar, and the range (minimum; maximum) is specified below each bar. alpha-glucosidase inhibitors, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide-1 receptor agonists, glycosylated hemoglobin, insulin, metformin, sodium-glucose co-transporter 2 inhibitors, sulfonylureas, thiazolidinediones